Oric Pharmaceuticals, Inc. (ORIC)

ORIC Pharmaceuticals' stock price has experienced notable events in the past six months. The share price was $9.05 as of April 8, 2026, a 92.96% increase over the past year. However, on April 1, 2026, the stock traded down 24% to $9.60 following the announcement of its Phase 3 dose selection for rinzimetostat. In Q4 2025, the company reported ($0.30) EPS, beating estimates, and shares gained +14.6%. In Q3 2025, EPS was ($0.33), with a +0.5% price effect. The company also held a Rinzimetostat Program Update Call on March 31, 2026.

As a clinical-stage biopharmaceutical company, ORIC Pharmaceuticals does not have commercialized products or services, so there is no traditional demand seasonality. The company's value is primarily driven by clinical milestones, research and development advancements, partnerships, and intellectual property.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies that overcome resistance mechanisms in cancer. The company operates in the healthcare sector, specifically in biotechnology, drug discovery, pharmaceuticals, and oncology. ORIC's mission is to improve the lives of cancer patients by addressing resistance to existing treatments. Its pipeline includes ORIC-944 (rinzimetostat) for prostate cancer, ORIC-114 (enozertinib) for multiple genetically defined cancers, and ORIC-533 for chemotherapy and immunotherapy resistance.

ORIC Pharmaceuticals is headquartered in South San Francisco, California, with additional offices in San Diego, California. The company's primary operational strength is in North America, with select ex-U.S. trial sites and potential for international expansion through partners and collaborations.

ORIC Pharmaceuticals has generally maintained a positive brand reputation among analysts, with a consensus rating of "Moderate Buy". Eleven analysts have given a "buy" recommendation, two a "hold," and one a "sell," with an average 12-month price objective of $19.90. However, the stock dropped significantly after the Phase 3 dose selection announcement for rinzimetostat. An insider sale by CFO Dominic Piscitelli could also be perceived negatively.

ORIC Pharmaceuticals has a significant institutional ownership base. As of April 9, 2026, 167 institutional owners and shareholders held a total of 107,524,830 shares. Major institutional shareholders include EcoR1 Capital, LLC, Viking Global Investors Lp, BlackRock, Inc., VR Adviser, LLC, Pfizer Inc, Vanguard Group Inc, Sr One Capital Management, Lp, Alkeon Capital Management Llc, State Street Corp, and NEA Management Company, LLC. Insider ownership accounted for 6.82% as of July 30, 2025.